Moderna recently announced that two doses of its COVID-19 vaccine showed a robust neutralizing antibody response in children six to under 12 years of age.
The Phase 2/3 KidCOVE randomized...
Pfizer and BioNTech recently announced that their COVID-19 vaccine booster was 95.6 percent effective in individuals compared to placebo.
The randomized, controlled Phase 3 trial...
CDC recently recommended Johnson & Johnson and Moderna’s COVID-19 vaccine booster shots for all eligible individuals who receive any FDA authorized vaccine.
The organization...
FDA recently granted emergency use authorization to both the Moderna and Johnson & Johnson respective COVID-19 vaccine booster doses.
The agency specifically approved Moderna’s booster...
FDA recently approved Rethymic to treat pediatric patients with rare disease congenital athymia.
Congenital athymia is a rare immune disorder in which a child is born without a thymus. The...
FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recently recommended a booster dose of Moderna’s COVID-19 vaccine, mRNA-1273, at the 50 microgram...
FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) recently recommended emergency use authorization for a booster dose of Johnson & Johnson’s COVID-19 vaccine.
VRBPAC...
AstraZeneca recently announced that its COVID-19 antibody, AZD7442, reduced severe COVID-19 or death compared to placebo in non-hospitalized patients with mild-to-moderate symptomatic...
Johnson & Johnson recently submitted data to the FDA to support its COVID-19 vaccine booster shot in adults 18 and older.
The submission includes results from the Phase 3 ENSEMBLE study, which...
Johnson & Johnson recently initiated a Phase 3 clinical trial to study its RSV vaccine's efficacy, safety, and immunogenicity against lower respiratory tract disease (LRTD) in adults.
The...
Regeneron recently announced that its COVID-19 antibody cocktail, REGEN-COV, significantly reduced viral load in patients hospitalized with the coronavirus.
The trial enrolled 1,197 patients to...
FDA recently approved Abbott’s Epic Plus and Epic Plus Supra Stented Tissue Value to improve therapy options for individuals with mitral or aortic valve disease.
The next-generation devices...
Pfizer recently announced the start of a Phase 2/3 study to evaluate its COVID-19 treatment in combination with ritonavir to prevent coronavirus disease.
The randomized, double-blind EPIC-PEP study...
Nearly 44 percent of adults ranked staying up to date on vaccines as important before the COVID-19 pandemic, rising to 65 percent after the pandemic, according to a new survey by Kantar on behalf of...
Roche recently announced that Tecentriq elicited disease-free survival in patients with Stage II-IIA non-small cell lung cancer (NSCLC).
Data from the IMpower010 trial, published in The Lancet, found...
Johnson & Johnson recently announced that a booster shot of its COVID-19 vaccine elicited 94 percent protection against coronavirus in a Phase 3 clinical trial.
The largest real-world...
Merck recently announced that its pneumococcal 15-valent conjugate vaccine, Vaxneuvance, met key immunogenicity and safety endpoints in a Phase 3 clinical trial.
The PNEU-PED study enrolled...
CMS has issued a final rule allowing payers to negotiate prescription drug pricing based on how well these drugs work for patients, a policy that could reduce overall healthcare spending and...
